Nicholas Adams
Chief Executive Officer

Nicholas has over 20 years of experience in business development and has led business development groups at and been on the Executive Teams of Antisoma, Clavis Pharma, Redx Pharma, ReNeuron and most recently, OxSonics. Over this time he has led or been instrumental in a range of global deals (including in-and out-licensing, divestments, spin-outs, royalty buy-out and M&A) with Big Pharma and biotechs; the out-licensing and divestment deals have generated over US$240m. He started his career in clinical development, mainly in oncology, with Ciba-Geigy, Eisai and Cephalon. He has a degree in Biology and post-graduate diplomas from the College of Law, London.